News

Update for Hemophilia Associations

June 18, 2020

BioMarin is a global pharmaceutical company with more than 20 years of experience in developing medicines for rare genetic conditions.

BioMarin is pleased to update the community regarding our ongoing gene therapy clinical trial program in
hemophilia A. BioMarin’s investigational gene therapy for hemophilia A has not been approved for use; it is
in ongoing clinical trials evaluating its safety and efficacy.

Read the whole article here

Bleeding Disorders Association of South Carolina is a 501(c)3 non-profit organization and a chapter of the National Hemophilia Foundation and a member organization of Hemophilia Federation of America.

Our mission is to raise awareness for and advocate on behalf of persons with bleeding disorders and their families; provide education and supportive services; and promote ongoing research to improve the quality of life for those affected.

See our brochure (PDF) to learn more: DOWNLOAD

Brochure in Spanish: DOWNLOAD

Contact Us

How to Get Involved

Sign up for our newsletter

Member of The National Bleeding Disorders Foundation | View our Privacy Policy | Website managed by Blotter.com